EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)VergleichsstudieÄquivalenzstudieMultizentrische StudieOpen Access

Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia

Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group, Todd C Lee iD, Lauren A Barina, Genevieve Walls, Anna L Goodman, Dafna Yahav, Matthew P Cheng, Marc Bonten, Asha C Bowen iD, Tom Boyles, Nick Daneman, Miquel B Ekkelenkamp und 48 weitere

New England Journal of Medicine · 18.06.2026 · 394 (23) · 2329-2339

DOI: 10.1056/nejmoa2506905 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift New England Journal of Medicine, erschienen am 18.06.2026. Verfasst von Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, McGill University, Montreal. Hauptthemen laut MEDLINE: Bacteremia, Cefazolin, Cloxacillin, Floxacillin. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, NIH HHS, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteremiaCefazolinCloxacillinFloxacillinStaphylococcal InfectionsStaphylococcus aureusAcute Kidney InjuryAgedFemaleHumansMaleMiddle AgedAnti-Bacterial AgentsBayes TheoremFirst Generation CephalosporinsIncidenceTreatment Outcome

Substanzen

Anti-Bacterial AgentsCefazolinCloxacillinFirst Generation CephalosporinsFloxacillin

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, McGill University, Montreal.
  • Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Department of Infectious Diseases, Division of Medicine, Middlemore Hospital, Auckland, New Zealand.
  • University College London Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London.
  • Department of Infection, Guy's and St. Thomas' National Health Service (NHS) Foundation Trust and King's College London, London.
  • Infectious Diseases Unit, Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Todd C Lee, Asha C Bowen, Achim J Kaasch, Cesar A Arias

Förderung

  • CIHR
  • NIH HHS
  • ZonMw
  • Department of Health, Australian Government
  • Health Research Council of New Zealand
  • NIAID NIH HHS
  • National Health and Medical Research Council
  • National Medical Research Council

Zitieren

APA

Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group, Lee, T. C., Barina, L. A., Walls, G., Goodman, A. L., Yahav, D., Cheng, M. P., Bonten, M., Bowen, A. C., Boyles, T., Daneman, N., Ekkelenkamp, M. B., Ghanem-Zoubi, N., Hensgens, M. P. M., Jager, N. G. L., Kaasch, A. J., Kouijzer, I. J. E., Lewis, R. J., Lumley, T., …, & Boyd, M. A. (2026). Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia. New England Journal of Medicine, 394(23), 2329-2339. https://doi.org/10.1056/nejmoa2506905

Vancouver

Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group, Lee TC, Barina LA, Walls G, Goodman AL, Yahav D, et al. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia. New England Journal of Medicine. 2026;394(23):2329-2339. doi:10.1056/nejmoa2506905

BibTeX
@article{StaphylococcusaureusNetworkAdaptivePlatformSNAPTrialGroup2026,
  author = {Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group, Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group and Lee, Todd C and Barina, Lauren A and Walls, Genevieve and Goodman, Anna L and Yahav, Dafna and Cheng, Matthew P and Bonten, Marc and Bowen, Asha C and Boyles, Tom and Daneman, Nick and Ekkelenkamp, Miquel B and Ghanem-Zoubi, Nesrin and Hensgens, Marjolein P M and Jager, Nynke G L and Kaasch, Achim J and Kouijzer, Ilse J E and Lewis, Roger J and Lumley, Thomas and Lye, David C and McDonald, Emily G and McKew, Genevieve and McLean, Alistair R D and McMullan, Brendan J and McQuilten, Zoe K and Morpeth, Susan C and Paterson, David L and Roberts, Jason A and Robinson, J Owen and Saito, Hiroki and Scarborough, Matthew and Ten Oever, Jaap and Turner, Rebecca M and Tverring, Jonas and van Hal, Sebastiaan J and Webb, Steve A and Whiteway, Lynda M and Arias, Cesar A and Henderson, Andrew and Heriot, George S and Snelling, Tom L and Afra, Kevin and Ali, Shabinah S and Amit, Sharon and Anagnostou, Nicholas A and Archuleta, Sophia and Aston, Stephen J and Athan, Eugene and Baharav, Nadav and Bai, Anthony D and Barber, Bridget E and Baskaran, Abinayah and Berkeley, Michelle M A and Best, Emma J and Bhilave, Nilesh R and Bloomfield, Max G and Bond, Katherine A and Bostock, Jennifer and Botheras, Carly L and Boyd, Mark A},
  title = {Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {23},
  pages = {2329--2339},
  doi = {10.1056/nejmoa2506905}
}
Kostenlos starten →